Here are some of the world's health agencies who have declared that rather than the ignorant 'puberty blockers are safe', that these drugs show very low evidence of improvement.
the NICE finding
arms.nice.org.uk/resources/hub/1070905/attachment
The summary of the conclusion is
Conclusion
The results of the studies that reported impact on the critical outcomes of gender dysphoria and mental health (depression, anger and anxiety), and the important outcomes of body image and psychosocial impact (global and psychosocial functioning), in children and adolescents with gender dysphoria are of very low certainty using modified GRADE. They suggest little change with GnRH analogues from baseline to follow-up.
This is a report on The Swedish changes - based on lack of evidence.
genderreport.ca/the-swedish-u-turn-on-gender-transitioning/
(People should seek original source from Sweden if they are going to dismiss this article. Fight the contents of the article, don't fucking just dismiss the publisher).
Australia and NZ College of Psychiatrists publish a warning there is not enough evidence.
//www.ranzcp.org/news-policy/policy-and-advocacy/position-statements/gender-dysphoria
The Royal Australian and New Zealand College of Psychiatrists have now updated their guidance.
They are now warning that there is NOT ENOUGH evidence to recommend affirming only treatments or indeed any particular treatment plan. They now say that underlying health issues should be treated at the same time. And warn that medicalisation of children and teens be very careful and thoroughly explored considering the ‘paucity’ of evidence at this time.
France - declares there is not enough evidence.
The latest from National Academy of Medicine, France. They have issued a press release about treatment for gender disphoria in children and adolescents.
SEGM have translated it, but also linked up the original version.
segm.org/France-cautions-regarding-puberty-blockers-and-cross-sex-hormones-for-youth
Extract
Transgender identity is a feeling of identifying as a gender different from that assigned at birth, which is persistent and lasts more than 6 months. This experience can cause significant and prolonged distress, which can contribute to an increased risk of suicide [a].
No genetic predisposition has been found.
While this condition has been long recognized, a sharp increase in demand for medical interventions has been observed (1,2) first in North America, then in Northern Europe, and, more recently, in France, particularly among children and adolescents. A recent study of a number of high schools in Pittsburgh revealed a prevalence that is clearly higher than previously estimated in the United States (3): 10% of students declared themselves to be transgender or non-binary or were unsure of their gender [b]. In 2003, the Royal Children's Hospital in Melbourne diagnosed only one child with gender dysphoria, whereas today it treats nearly 200.
Whatever the mechanisms involved in adolescents - excessive engagement with social media, greater social acceptability, or influence by those in one’s social circle - this epidemic-like phenomenon manifests itself in the emergence of cases or even clusters of cases in the adolescents’ immediate surroundings (4). This primarily social problem is due, in part, to the questioning of an overly dichotomous view of gender identity by some young people.
The demand for medical interventions, due to the distress that this condition (which is not a mental illness per se) causes, leads to a growing supply of care in the form of consultations or care in specialized clinics. This involves many pediatric subspecialties. The psychiatric consultations are utilized first, and if the identity is authentic and the discomfort persists, endocrinology, gynecology and, ultimately, surgery become involved.
However, great medical caution must be taken in children and adolescents, given the vulnerability, particularly psychological, of this population and the many undesirable effects and even serious complications that can be caused by some of the therapies available. In this regard, it is important to recall the recent decision (May 2021) of the Karolinska University Hospital in Stockholm to prohibit the use of puberty blockers.
If France allows the use of puberty blockers or cross-sex hormones with parental authorization and no age limitations, the greatest caution is needed in their use, taking into account the side-effects such as the impact on growth, bone weakening, risk of sterility, emotional and intellectual consequences and, for girls, menopause-like symptoms.
UK The Cass Review Interim Report - stating there is not enough evidence!
cass.independent-review.uk/wp-content/uploads/2022/03/The-Cass-Review-Interim-Report-Final-Bookmarked.pdf
Here is an article on the the World Health Organisation's flip flop. WHO clarifies that “gender-affirmative care” is not supported by evidence in children and adolescents.
https://segm.org/WHO-TGD-Guideline-Concerns-2024
So, come on all those declaring these drugs are 'safe'. Please show the world your evidence that these countries have not had access to.